CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M SESTAMIBI KIT
✉ Email this page to a colleague
All Clinical Trials for TECHNETIUM TC-99M SESTAMIBI KIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00162045 ↗ | A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects | Completed | Lantheus Medical Imaging | Phase 1/Phase 2 | 2005-01-01 | The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects. |
| NCT00162071 ↗ | A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging | Terminated | Forest Laboratories | Phase 2 | 2005-07-01 | The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied. |
| NCT00560495 ↗ | Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | Withdrawn | National Cancer Institute (NCI) | Phase 1 | 2007-05-01 | RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer. |
| NCT00560495 ↗ | Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer | Withdrawn | Roswell Park Cancer Institute | Phase 1 | 2007-05-01 | RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer. |
| NCT00767468 ↗ | Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis | Terminated | National Cancer Institute (NCI) | Phase 1 | 2008-10-01 | RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TECHNETIUM TC-99M SESTAMIBI KIT
Condition Name
| Condition Name for TECHNETIUM TC-99M SESTAMIBI KIT | |
| Intervention | Trials |
| Cardiovascular Disease | 1 |
| Triple-Negative Breast Carcinoma | 1 |
| Constipation-predominant Irritable Bowel Syndrome | 1 |
| Estrogen Receptor Negative | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for TECHNETIUM TC-99M SESTAMIBI KIT
Trials by Country
Clinical Trial Progress for TECHNETIUM TC-99M SESTAMIBI KIT
Clinical Trial Phase
Clinical Trial Sponsors for TECHNETIUM TC-99M SESTAMIBI KIT
Sponsor Name
